FACS analysis of HEK293T cells transfected with either alpha 1 Antitrypsin plasmid(Red) or empty vector control plasmid(Blue) using GTX83666 alpha 1 Antitrypsin antibody [9A1].

IHC-P analysis of human endometrium adenocarcinoma tissue using GTX83666 alpha 1 Antitrypsin antibody [9A1].
Antigen retrieval : Heat-induced epitope retrieval by 10mM citrate buffer, pH6.0, 100ºC for 10min.

IHC-P analysis of human pancreas tissue using GTX83666 alpha 1 Antitrypsin antibody [9A1].
Antigen retrieval : Heat-induced epitope retrieval by 10mM citrate buffer, pH6.0, 100ºC for 10min.

WB analysis of human tissues (Lane 1-Uterus ; Lane 2-Breast ; Lane 3-Brain ; Lane 4-Liver ; Lane 5-Ovary ; Lane 6-Thyroid gland ; Lane 7-colon) using GTX83666 alpha 1 Antitrypsin antibody [9A1].
Loading : 10 ug per lane
Dilution : 1:200

WB analysis of various cell lines using GTX83666 alpha 1 Antitrypsin antibody [9A1].
Loading : 35 ug per lane

IHC-P analysis of human liver carcinoma tissue using GTX83666 alpha 1 Antitrypsin antibody [9A1].
Antigen retrieval : Heat-induced epitope retrieval by 10mM citrate buffer, pH6.0, 100ºC for 10min.

IP analysis of DDDDK tagged alpha 1 Antitrypsin overexpressed HEK293T lysate using GTX83666 alpha 1 Antitrypsin antibody [9A1].After extensive wash to remove any non-specific binding, the immuno-precipitated products were analyzed with rabbit anti-DDDDK polyclonal antibody.
IP reaction : 2μg antibody / 500μl cell lysate

WB analysis of HEK293T cells transfected with alpha 1 Antitrypsin plasmid (Right) or empty vector (Left) for 48 hrs using GTX83666 alpha 1 Antitrypsin antibody [9A1].
Loading : 5 ug per lane

IHC-P analysis of human liver tissue using GTX83666 alpha 1 Antitrypsin antibody [9A1].
Antigen retrieval : Heat-induced epitope retrieval by 10mM citrate buffer, pH6.0, 100ºC for 10min.

IHC-P analysis of human thyroid carcinoma tissue using GTX83666 alpha 1 Antitrypsin antibody [9A1].
Antigen retrieval : Heat-induced epitope retrieval by 10mM citrate buffer, pH6.0, 100ºC for 10min.

The data was published in the 2022 in JCI Insight. PMID: 35104244